Abstracts tagged "Pathology Bone Joint"

Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
Abstract Number: 1890 • ACR Convergence 2021
Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
Hannah Nelson¹, Ellen Gravallese², Julia Charles¹ and Christian Jacome-Galarza¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 0793 • ACR Convergence 2020
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
Benjamin Van Espen¹, Andrew Wilson¹, Gregory Seumois², Narayanan Perumal³, Robert Benschop⁴, Gary Firestein⁵, Nunzio Bottini⁵ and Stephanie Stanford¹, ¹University of California, San Diego, La Jolla, ²La Jolla Institute for Immunology, La Jolla, ³Eli Lilly, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of California, San Diego, La Jolla, CA
Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…
Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Hayley Carr¹, Ilfita Sahbudin¹, Mark Maybury¹, Bernard Dyke², Jason Turner³, Nicola Gullick⁴, Karim Raza⁵, Dagmar Scheel-Toellner¹ and Andrew Filer¹, ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Iain McInnes¹, Hector Chinoy², Darren Asquith³, Abigail White³ and Corine Gaillez⁴, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Novartis Pharmaceuticals UK Ltd., London, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…
Abstract Number: 1854 • ACR Convergence 2020
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Siba Raychaudhuri¹ and Smriti Raychaudhuri², ¹UC Davis, School of Medicine, Davis, CA, ²VA Sacramento Medical Center, Davis, CA
Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…